ロード中...
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer
Pancreatic cancer (PDAC) is still lacking of reliable markers to monitor tumor response. CA 19-9 is the only biomarker approved, despite it has several limitations in sensitivity and specificity. Since mutations of KRAS occur in more than 90% of tumors, its detection in circulating free tumor DNA (c...
保存先:
| 出版年: | Sci Rep |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5554237/ https://ncbi.nlm.nih.gov/pubmed/28801547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-08297-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|